DNLI news

Denali Therapeutics entered a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in gross proceeds following FDA approval of AVLAYAH for Hunter syndrome. The proceeds will fund advancement of the company's clinical pipeline for lysosomal storage disorder…

The Phase 2b LUMA study of BIIB122 failed to meet primary and secondary endpoints in early-stage Parkinson's disease, prompting discontinuation in idiopathic PD while continuing a separate LRRK2 carrier study. The setback represents a significant clinical disappointment for both companies in the neu…